AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22084332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran, 150 mg twice daily
Number of subjects: 18112
Study 22084332 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18112
Study 22084332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran, 150 mg or 110 mg twice daily
Number of subjects: 18112
Study 19370286 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care education
Number of subjects: 80
Study 19370286 — intervention group
Group type: COMPARATOR
Intervention: Control group (no self-care education)
Number of subjects: 80
Study 16877072 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.15% preserved with polyquaternium-1 (brimonidine PQ)
Number of subjects: 842
Study 16877072 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine tartrate 0.15% preserved with chlorine dioxide (brimonidine P)
Number of subjects: 842
Study 12810936 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention by occupational specialists involving information about the disorder, encouragement to stay active, and instruction in graded self‐performed exercises.
Number of subjects: 266
Study 12810936 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention by occupational specialists
Number of subjects: 266
Study 12810936 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (usual approach in general practice)
Number of subjects: 266
Study 15505965 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-route model treatment
Number of subjects: 44
Study 15505965 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-route model treatment
Number of subjects: 44
Study 15505965 — intervention group
Group type: COMPARATOR
Intervention: Control treatments
Number of subjects: 44
Study 9176041 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa (100 mg)
Number of subjects: 25
Study 9176041 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg)
Number of subjects: 25
Study 9176041 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 25
Study 1585899 — intervention group
Group type: COMPARATOR
Intervention: Placebo recipients (20,744)
Number of subjects: 32642
Study 3982903 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram therapy
Number of subjects: 26
Study 3982903 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline therapy
Number of subjects: 26
Study 3982903 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline plus doxapram therapy
Number of subjects: 26
Study 3982903 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline plus placebo
Number of subjects: 26
Study 28902114 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer plus RS-COD training program
Number of subjects: 29
Study 28902114 — intervention group
Group type: COMPARATOR
Intervention: Soccer-only group
Number of subjects: 29
Study 28902114 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-COD training
Number of subjects: 29
Study 29140864 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mL 0.5% bupivacaine with 1:200,000 epinephrine (Group A)
Number of subjects: 51
Study 29140864 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mL of 1% lidocaine with 1:100,000 epinephrine (Group B)
Number of subjects: 51
Study 26581198 — intervention group
Group type: EXPERIMENTAL
Intervention: Introductory presentation plus workshop
Number of subjects: 395
Study 26581198 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissemination by student representatives/peers
Number of subjects: 395
Study 26581198 — intervention group
Group type: COMPARATOR
Intervention: Advertisement materials only
Number of subjects: 395
Study 24946636 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedding therapy on back‐shu points and front‐mu points and needle‐pricking therapy on Sifeng (EX‐UE 10)
Number of subjects: 85
Study 24946636 — intervention group
Group type: COMPARATOR
Intervention: Metformin hydrochloride tablet (0.5 g, once a day for the first week, twice a day from the second week)
Number of subjects: 85
Study 22325731 — intervention group
Group type: EXPERIMENTAL
Intervention: Handrubbing with alcohol covering all hand surfaces
Number of subjects: 120
Study 22325731 — intervention group
Group type: EXPERIMENTAL
Intervention: Handrubbing with alcohol using the standard 7-step technique
Number of subjects: 120
Study 22325731 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing with chlorhexidine using the standard 7-step technique
Number of subjects: 120
Study 19650983 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free formula feeding
Number of subjects: 120
Study 19650983 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula feeding
Number of subjects: 120
Study 17500623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR treatment
Number of subjects: 323
Study 17500623 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of DRD2 A1 allele and SLC6A3 status
Number of subjects: 323
Study 17500623 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of DRD2 A1 allele and SLC6A3 status
Number of subjects: 323
Study 14697476 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 847
Study 14697476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 847
Study 12114418 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (400 mg/day given p.o.)
Number of subjects: 261
Study 9686713 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic postcard
Number of subjects: 24743
Study 9686713 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized postcard from their physician
Number of subjects: 24743
Study 9686713 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized letter from their physician, tailored to their health risk
Number of subjects: 24743
Study 9686713 — intervention group
Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 24743
Study 8026259 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily (group A)
Number of subjects: 45
Study 8026259 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg on weekends (group B)
Number of subjects: 45
Study 8026259 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg every other day (group C)
Number of subjects: 45
Study 8026259 — intervention group
Group type: EXPERIMENTAL
Intervention: All three dose regimens of omeprazole
Number of subjects: 45
Study 8026259 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily (group A), Omeprazole 40 mg on weekends (group B), Omeprazole 20 mg every other day (group C)
Number of subjects: 45
Study 2918132 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish (group I)
Number of subjects: 26
Study 2918132 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (group II)
Number of subjects: 26
Study 2918132 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (group III)
Number of subjects: 26
Study 2918132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-plus-chlorhexidine varnish (group IV)
Number of subjects: 26
Study 2918132 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (second treatment)
Number of subjects: 26
Study 30979589 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-CET (cetuximab plus carboplatin and paclitaxel)
Number of subjects: 108
Study 30979589 — intervention group
Group type: COMPARATOR
Intervention: CP (carboplatin and paclitaxel)
Number of subjects: 108
Study 28328795 — intervention group
Group type: COMPARATOR
Intervention: HBsAg positivity in Zimbabwe (12.2%) vs. Uganda (7.7%)
Number of subjects: 3316
Study 28328795 — intervention group
Group type: COMPARATOR
Intervention: HBeAg detection among HBsAg-positive patients (37%)
Number of subjects: 3316
Study 28328795 — intervention group
Group type: COMPARATOR
Intervention: HBV DNA status in HBsAg-positive patients
Number of subjects: 3316
Study 28328795 — intervention group
Group type: COMPARATOR
Intervention: Detectable HBV DNA in HBeAg-positive (96%) vs. HBeAg-negative (70%) patients
Number of subjects: 3316
Study 26817306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sertraline hydrochloride at 50 mg qd for 12 weeks
Number of subjects: 90
Study 26817306 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-spot caressing for 12 weeks
Number of subjects: 90
Study 26817306 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral sertraline hydrochloride and four-spot caressing for 12 weeks
Number of subjects: 90
Study 23229158 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month print-based theory tailored physical activity intervention (n = 224)
Number of subjects: 448
Study 23229158 — intervention group
Group type: COMPARATOR
Intervention: 6-month health/wellness contact control arm (n = 224)
Number of subjects: 448
Study 21626284 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 125 ng
Number of subjects: 13
Study 21626284 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 250 ng
Number of subjects: 13
Study 21626284 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 500 ng
Number of subjects: 13
Study 21626284 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 250 ng and 500 ng
Number of subjects: 13
Study 21626284 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 500 ng i.v.
Number of subjects: 13
Study 17347165 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 78
Study 17347165 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 78
Study 15132126 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (single dose)
Number of subjects: 23
Study 15132126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12581546 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 and 24 microg)
Number of subjects: 20
Study 12581546 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (180 microg)
Number of subjects: 20
Study 12581546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9789694 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) administered intracoronarily at a dosage of 25 ng/kg/min for 8 min during the second balloon inflation.
Number of subjects: 15
Study 9789694 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) administered intracoronarily.
Number of subjects: 15
Study 9789694 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (control group).
Number of subjects: 15
Study 8728803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary isosorbide mononitrate (ISMN) 20 mg
Number of subjects: 40
Study 8728803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2676063 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-field (0.08 T) magnetic resonance (MR) imaging
Number of subjects: 124
Study 145654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized fenoterol
Number of subjects: 0
Study 145654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized salbutamol
Number of subjects: 0
Study 145654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized ipratropium bromide
Number of subjects: 0
Study 145654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized terbutaline
Number of subjects: 0
Study 145654 — intervention group
Group type: COMPARATOR
Intervention: Administration by investigator
Number of subjects: 0
Study 145654 — intervention group
Group type: COMPARATOR
Intervention: Self-administration by patients
Number of subjects: 0
Study 30995611 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose IR images
Number of subjects: 10
Study 30995611 — intervention group
Group type: EXPERIMENTAL
Intervention: Half and quarter doses
Number of subjects: 10
Study 30995611 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered back projection (FBP) and iterative reconstruction (IR) algorithms
Number of subjects: 10
Study 28399633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet not inflated
Number of subjects: 50
Study 28399633 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet inflated
Number of subjects: 50
Study 26151886 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban intake at 08:00 h
Number of subjects: 16
Study 26151886 — intervention group
Group type: COMPARATOR
Intervention: No rivaroxaban intake
Number of subjects: 16
Study 26151886 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban intake at 20:00 h
Number of subjects: 16
Study 23391126 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive voice response (IVR) outreach
Number of subjects: 24167
Study 23391126 — intervention group
Group type: COMPARATOR
Intervention: Control (mailed outreach or natural levels of inbound calling)
Number of subjects: 24167
Study 21699587 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mL of oral supplement and dietary advice
Number of subjects: 125
Study 21699587 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice alone
Number of subjects: 125
Study 21699587 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzby definition for surgical site infections in weight-losing patients
Number of subjects: 125
Study 18408265 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil pulling with sesame oil for 10 min every day before brushing
Number of subjects: 20
Study 18408265 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash for 10 min every day before brushing
Number of subjects: 20
Study 17227607 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching protocol, online tutorial, skills building workshop and performance feedback
Number of subjects: 41
Study 17227607 — intervention group
Group type: COMPARATOR
Intervention: Usual practices (Control)
Number of subjects: 41
Study 15013471 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone supplementation
Number of subjects: 0
Study 15013471 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thyroid hormone supplementation)
Number of subjects: 0
Study 12199262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl
Number of subjects: 0
Study 12199262 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine tablets
Number of subjects: 0
Study 9718255 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous film
Number of subjects: 200
Study 9718255 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer film (regardless of type)
Number of subjects: 200
Study 9718255 — intervention group
Group type: EXPERIMENTAL
Intervention: Holocaust film
Number of subjects: 200
Study 9718255 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral film
Number of subjects: 200
Study 9718255 — intervention group
Group type: COMPARATOR
Intervention: No-film group
Number of subjects: 200
Study 8110568 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 40 ml with morphine 5 mg (group BM5)
Number of subjects: 58
Study 8110568 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 40 ml with morphine 2 mg (group BM2)
Number of subjects: 58
Study 8110568 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% 40 ml only (group B0)
Number of subjects: 58
Study 2761061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (1.2 g)
Number of subjects: 38
Study 2761061 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 38
Study 779054 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (mean dose: 158 ± 9 mg per day)
Number of subjects: 31
Study 779054 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (mean dose: 1540 ± 90 mg per day)
Number of subjects: 31
Study 779054 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 31
Study 31160472 — intervention group
Group type: EXPERIMENTAL
Intervention: VR interactive game
Number of subjects: 64
Study 31160472 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (topical numbing cream, positioning, distraction by a specialized pain nurse)
Number of subjects: 64
Study 31160472 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 64
Study 28385431 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-polymerizing cement
Number of subjects: 10
Study 28385431 — intervention group
Group type: COMPARATOR
Intervention: Dual-polymerizing cement
Number of subjects: 10
Study 28385431 — intervention group
Group type: EXPERIMENTAL
Intervention: Both light- and dual-polymerizing modes
Number of subjects: 10
Study 25908703 — intervention group
Group type: EXPERIMENTAL
Intervention: CPMHA (Belotero Balance)
Number of subjects: 30
Study 25908703 — intervention group
Group type: EXPERIMENTAL
Intervention: CPMHA with lidocaine (BEL‐L)
Number of subjects: 30
Study 25908703 — intervention group
Group type: EXPERIMENTAL
Intervention: CPMHA with lidocaine and epinephrine (BEL‐LE)
Number of subjects: 30
Study 25908703 — intervention group
Group type: COMPARATOR
Intervention: Control: CPMHA (Belotero Balance)
Number of subjects: 30
Study 25908703 — intervention group
Group type: COMPARATOR
Intervention: Control: CPMHA with lidocaine (BEL‐L)
Number of subjects: 30
Study 25908703 — intervention group
Group type: COMPARATOR
Intervention: Control: CPMHA with lidocaine and epinephrine (BEL‐LE)
Number of subjects: 30
Study 23521871 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive quetiapine (QTP)
Number of subjects: 55
Study 23521871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 55
Study 21226678 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (5 mg)
Number of subjects: 25
Study 21226678 — intervention group
Group type: COMPARATOR
Intervention: Sleep inertia (placebo)
Number of subjects: 25
Study 21226678 — intervention group
Group type: COMPARATOR
Intervention: Wakefulness control (placebo)
Number of subjects: 25
Study 20178218 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide bleaching agent (Pola Night) for 2 hours a day for 3 weeks
Number of subjects: 20
Study 20178218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bleaching treatment)
Number of subjects: 20
Study 17976099 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT group
Number of subjects: 30
Study 17976099 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 15379110 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hospitalization
Number of subjects: 0
Study 15379110 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care in a general hospital ward
Number of subjects: 0
Study 11689755 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% clindamycin phosphate vaginal cream
Number of subjects: 79
Study 11689755 — intervention group
Group type: COMPARATOR
Intervention: Triple sulfonamide vaginal cream
Number of subjects: 79
Study 9387133 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO) given intravenously for 8 weeks at 50 Ul/kg body weight three times a week, then subcutaneously for 4 weeks at 25 Ul/kg body weight twice a week, and for the last 8 weeks at 25 Ul/kg body weight once a week.
Number of subjects: 25
Study 7696452 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide retention enema (2.3 mg/115 mL)
Number of subjects: 100
Study 7696452 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone disodium phosphate enema (31.25 mg/125 mL)
Number of subjects: 100
Study 2902920 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 42
Study 2902920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 30043086 — intervention group
Group type: EXPERIMENTAL
Intervention: Swan neck coiled tip catheter
Number of subjects: 46
Study 30043086 — intervention group
Group type: COMPARATOR
Intervention: Swan neck straight tip catheter
Number of subjects: 46
Study 30097333 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zolpidem
Number of subjects: 13
Study 30097333 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 13
Study 30097333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 27263164 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfora Bullet Cage System (ABCS)
Number of subjects: 257
Study 27263164 — intervention group
Group type: COMPARATOR
Intervention: Medtronic‐Sofamor Danek Inter Fix Threaded Fusion Device (MSDIFD)
Number of subjects: 257
Study 24368344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia hospitalization
Number of subjects: 3069
Study 24368344 — intervention group
Group type: EXPERIMENTAL
Intervention: Other infections hospitalization
Number of subjects: 3069
Study 22767144 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m² plus Irinotecan 250 mg/m² (Day 1)
Number of subjects: 85
Study 22767144 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 85 mg/m² (Day 1) followed by 5-fluorouracil 750 mg/m² per day (Days 1-5)
Number of subjects: 85
Study 20646829 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisiphon group (Vygon shunt)
Number of subjects: 40
Study 20646829 — intervention group
Group type: COMPARATOR
Intervention: Non-antisiphon group (Chhabra shunt and Ceredrain)
Number of subjects: 40
Study 17195712 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertussis immune globulin (P‐IGIV)
Number of subjects: 25
Study 17195712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 15947625 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month liquid diet weight reduction program
Number of subjects: 48
Study 15947625 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 48
Study 12133144 — intervention group
Group type: EXPERIMENTAL
Intervention: Online lecture on screening
Number of subjects: 95
Study 12133144 — intervention group
Group type: COMPARATOR
Intervention: Live lecture on screening
Number of subjects: 95
Study 12133144 — intervention group
Group type: EXPERIMENTAL
Intervention: Online lecture with audio feed
Number of subjects: 95
Study 12133144 — intervention group
Group type: EXPERIMENTAL
Intervention: Online lecture without audio feed
Number of subjects: 95
Study 9472866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pima Action
Number of subjects: 95
Study 9472866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pima Pride
Number of subjects: 95
Study 9472866 — intervention group
Group type: COMPARATOR
Intervention: Observational group
Number of subjects: 95